Key Findings
Bioseon has released comprehensive ‘Proof-Driven Operating Guides’ designed to enable autonomous biologics manufacturing. These guides integrate soft sensors, Process Analytical Technology (PAT) streams, and bioreactor digital twins to facilitate real-time control of live titer and Critical Quality Attributes (CQAs), thereby dramatically enhancing the efficiency and quality consistency of biomanufacturing.
Technical / Clinical Details
The core technology behind these operating guides is autonomous process control, combining AI with advanced sensing technologies:
- **Soft Sensors**: These estimate parameters like titer and CQAs, which are difficult to measure directly with physical sensors, in real-time by combining existing sensor data (e.g., temperature, pH, DO) with mathematical models. This enables inline quality monitoring.
- **PAT Streams**: Advanced process analytical technologies, such as Raman spectroscopy, are implemented to non-invasively and in real-time measure glucose, lactate, and target protein titers in cell culture media. This reduces the need for sampling and offline analysis, supporting rapid decision-making during the process.
- **Bioreactor Digital Twins**: These digitally replicate the behavior of physical bioreactors, allowing for simulation of various scenarios to identify optimal process conditions. This is crucial for responding to unexpected process variations and minimizing risks.
- **Autonomous Control Algorithms**: Based on data from soft sensors, PAT, and digital twins, AI-driven algorithms automatically adjust process parameters such as fed-batch feed rates, perfusion rates, and aeration. For example, systems have been realized that monitor real-time titer with Raman spectroscopy and automatically control feed supply to maintain target titers.
The integration of these technologies significantly enhances the robustness and reproducibility of manufacturing processes while minimizing human intervention.
Background & Context
Biopharmaceutical manufacturing demands high quality control and efficiency, but has historically been challenged by complex processes and significant time and cost expenditures. Manual sampling and offline analysis, in particular, have limited real-time insights into the process, leading to missed optimization opportunities. In recent years, the Industry 4.0 concept has been applied to biomanufacturing, driving a shift towards smart manufacturing leveraging digital technologies like AI, IoT, and big data. Bioseon’s operating guides accelerate this trend, providing a concrete roadmap for CDMOs and biopharma manufacturers to effectively integrate these advanced technologies into existing processes.
Strategic Significance & Outlook
The widespread adoption of autonomous biologics manufacturing will revolutionize the industry by improving product quality consistency, reducing manufacturing costs, shortening time-to-market, and stabilizing supply. Bioseon’s operating guides serve as practical tools for CDMOs and biopharma manufacturers to reap these benefits. In the future, fully autonomous ‘smart factories’ may become a reality, where biologics are produced without human intervention. Investors recognize such technological innovations as key drivers for improving biomanufacturing efficiency and profitability, and are focusing on investment opportunities in companies providing autonomous manufacturing solutions.
Source: https://www.bioseon.com/resources.html
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments